Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Oct 18.
Published in final edited form as: J Immunol. 2023 Nov 1;211(9):1385–1396. doi: 10.4049/jimmunol.2300107

Impact of Mycobacterium tuberculosis glycolipids on the CD4+ T cell-macrophage immunological synapse

Ivan Mwebaza *, Rachel Shaw *, Qing Li *, Shane Fletcher *, Jacqueline M Achkar @, Clifford V Harding *,#,&, Stephen M Carpenter *,#,&, W Henry Boom *,#,&
PMCID: PMC10579150  NIHMSID: NIHMS1927963  PMID: 37695687

Abstract

Mycobacterium tuberculosis (Mtb) cell-wall glycolipids such as mannosylated lipoarabinomannan (ManLAM) can inhibit murine CD4+ T cells by blocking T cell receptor signaling. This results in suppression of IL-2 production, reduced T cell proliferation and induction of CD4+ T cell anergy. This study extended these findings to the interaction between primary human CD4+ T cells and macrophages infected by mycobacteria. Exposure of human CD4+ T cells to ManLAM prior to activation resulted in loss of polyfunctionality as measured by IL-2, IFN-γ, and TNF-α expression, and reduced CD25 expression. This was not associated with upregulation of inhibitory receptors CTLA-4, PD-1, TIM-3, and Lag-3. By confocal microscopy and imaging flow cytometry, ManLAM exposure reduced conjugate formation between macrophages and CD4+ T cells. ManLAM co-localized to the immunological synapse and reduced translocation of lymphocyte-specific protein tyrosine kinase (LCK) to the immunological synapse. When CD4+ T cells and BCG-infected monocytes were co-cultured, ManLAM co-localized to CD4+ T cells, which formed fewer conjugates with infected monocytes. These results demonstrate that mycobacterial cell wall glycolipids such as ManLAM can traffic from infected macrophages to disrupt productive immunological synapse formation and inhibit CD4+ T cell activation, contributing to immune evasion by Mtb.

Introduction.

Development of a better vaccine and immunotherapeutics against tuberculosis (TB) has been hampered by inadequate understanding of the interactions between Mycobacterium tuberculosis (Mtb), macrophages and T cells. Upon inhalation of aerosols Mtb bacilli are taken up by lung antigen presenting cells (APC) that process and present their antigens to cells of the adaptive immune response (1) (2). This cell mediated immune response should facilitate clearance of the organism (3). However, Mtb is not cleared in many infected individuals, surviving in granulomas as a latent Mtb infection (LTBI) (4) (5) and in some progressing to active disease (6)(7). Immune evasion by Mtb allows it to resist macrophage killing and recognition of infected APCs by T cells (8).

MHC class II (MHC-II)-restricted CD4+ T cells have a central role in the T cell response to Mtb. HIV-induced CD4+ T cell depletion provides strong evidence for a dominant role of human CD4+ T cells in controlling Mtb (9). Murine MHC-II knockout and non-human primate CD4+ T cell depletion studies experimentally support the importance of CD4+ T cells (10). CD4+ T cells expressing IFN-γ, TNF-α, and IL-2 are associated with protective responses to Mtb (11). CD4+ T cells from persons with LTBI recognize a diverse range of Ags (12), but since antigenic variation among Mtb strains is minimal this likely is not a major mechanism of immune evasion.

Molecular mechanisms used by Mtb to resist innate immune responses include disruption of phagolysosome fusion and resisting of killing by superoxide, autophagy, and apoptosis (13). Mtb also indirectly and directly interferes with recognition of infected cells by CD4+ T cells. Mtb lipoproteins activate TLR2 signaling in macrophages, which inhibits MHC-II antigen processing (5). Mtb’s secreted protein EsxH can interfere with T cell activation (14), and Mtb-infected dendritic cells can export antigens to uninfected cells as decoy for CD4+ T cells (15). Our recent studies have focused on Mtb glycolipids, especially ManLAM, as inhibitors of CD4+ T cell activation. Through direct contact with infected cells or release of bacterial micro-vesicles, CD4+ T cells are exposed to Mtb products, including lipids, proteins, and glycolipids such as ManLAM (16)(17)(18)(19). ManLAM can directly inhibit CD4+ T cells by blocking phosphorylation of proximal TCR kinases LCK, Zap70 and adaptor protein LAT resulting in downregulation of IL-2 expression, hypo-proliferation and anergy through the induction of Gene Related to Anergy in Lymphocytes (GRAIL) (16) (17, 19, 20).

While a critical insight into Mtb pathogenesis, the discovery and dissection of the mechanism of Mtb glycolipid-mediated inhibition of CD4+ T cell activation was performed in a murine experimental system (16) (17) (19) (20). In the current study we sought to determine the impact of ManLAM and mycobacterial infection on the interaction between human CD4+ T cells and macrophages with a particular focus on the immunological synapse. Using primary human CD4+ T cells, we determined the effect of ManLAM and Mycobacterium bovis BCG (BCG) infection on: (i) CD4+ T cell polyfunctionality, (ii) conjugate formation between CD4+ T cells and macrophages, (iii) the integrity of the immunological synapse and (iv) colocalization of ManLAM to CD4+ T cells when co-cultured with infected primary monocytes.

Materials and Methods

Ethics Statement

Human CD4+ T cell donors (N=12) were recruited and consented under the study “Heterogeneity of CD4+ T cells in M. tuberculosis infection” that was approved by the Institutional Review Board of University Hospitals Case Medical Center (IRB Number: 03-88-63). Normal CD4+ T cells and monocytes were also obtained from three adult donors by leukapheresis from AllCells, LLC (Almeda, CA, USA). In both cases, all samples were de-identified and the study was conducted under the ethical principles as specified in the Declaration of Helsinki.

Antibodies

CD4+ T cells were stimulated using monoclonal Abs (mAbs) anti-CD28 (Cat# 555725, BD Biosciences, CD28.2 clone) and anti-CD3ε (Cat#16-0037-81, eBioscience, OKT3 clone). The following mAbs were used for flow cytometric assays (unless otherwise stated, all antibodies were mouse anti-human mAbs), anti-CD3-BUV395, anti-ICOS-BV711, anti-PD-1-BV650, anti-CTLA-4-BV421, anti-CD40L-PE-CF594, anti-Lag-3-APC-R700, anti-IL-17A-BV421, anti-CD45RA-PE-CF594, anti-CD27-APC, anti-IFN-γ-PE, anti-TNF-α-AF700, anti-IL-2-BV650, anti-CD25-BUV395, anti-CD69-BV421 (Cat#564001, 563833, 564324, 565931, 563589, 565775, 562933, 565419, 558664, 559326, 557996, 563467, 567484, 562883, respectively, BD Biosciences) anti-CD4-APC-cy7, anti-TIM-3-PE/cy7, anti-CD28-FITC, anti-CD4-AF594 (cat#300518, 345014, 302906, 300544 respectively, BioLegend). Aqua dye (BV510, Cat#L34965, Thermofisher) was used for live-dead cell stain. Anti-CD3-AF488 (Cat# 300454, BioLegend), anti-CD14-PE (Cat# 562691, BD Biosciences), anti-LCK-AF647 (Cat# SC-433, Santa Cruz technologies) were used for imaging flow cytometry.

The following primary Abs were used for confocal microscopy: Rabbit anti-CD4 recombinant monoclonal (Cat#MA5-32166, Invitrogen), Mouse anti-LCK monoclonal (Cat# MA5-12303, Invitrogen), Mouse anti-CD14 monoclonal (STEM CELL 60004, or BD Biosciences 557152 (same clone: M5E2)), Rabbit anti-CD3 recombinant monoclonal (Abcam ab135372), Mouse anti CD86 monoclonal (Cat# 305435 BioLegend).

Human anti-ManLAM mAb (L1AM04) was isolated from PBMCs from an individual with LTBI via single B cell sorting with delipidated ManLAM glycan arabinomannan (21). This mAb was generated by cloning L1AM04’s heavy and light chain variable regions into human IgG1 heavy and light chain expression vectors followed by co-expression in 293 HEK cells and provided by Dr. J. Achkar (Albert Einstein College of Medicine). L1AM04 is distinct from other anti-ManLAM mAbs and reacts specifically with the ManLAM cap component Man3Ara4 (reviewed in Corrigan et al, 2023)(22). It binds to various lab and clinical Mtb strains, as well as BCG, and recognizes Mtb and ManLAM in the lungs of Mtb infected mice (21). Goat anti-Mouse IgG-AF488 (Cat# A11001, Invitrogen), goat anti-Rabbit IgG-AF594 (Cat# A11012, Invitrogen), and goat anti-human IgG-AF647 (Thermofisher CatA21445) were used as secondary antibodies.

Reagents

Mannosylated lipoarabinomannan (ManLAM) was provided by BEI Resources (NR-14848). Briefly, the glycolipid was purified from the cell wall of irradiated Mtb H37Rv strain by delipidation, ethanol precipitation and size exclusion chromatography. The lyophilized glycolipid was resuspended in 1xPBS at 1ug/uL, sonicated, aliquoted, and stored at −80°C.

Ammonium chloride, calcium chloride, and sucrose (Cat#; A4514, C-7902, and S5016 respectively) were purchased from Sigma-Aldrich (St. Louis, MO 68178). Paraformaldehyde (PFA) was purchased from Electron Microscopy Sciences (Industry Road, Hatfield, PA 19440). Recombinant human IL-2 (rIL-2, Cat#200-02) was purchased from Peprotech (Granbury,NJ).

Mycobacterium bovis BCG, Connaught (ATCC 35745, Manassas, VA) was grown as described in Qing L et al (23). Briefly, BCG was grown in Middlebrook 7H9 medium (BD diagnostics) supplemented with 10% albumin-dextrose-catalase (ADC) (Difco, Detroit, MI) and glycerol (6%v/v). Cyan fluorescent protein-expressing BCG (BCG/CFP) was made by transformation with plasmid pDH3 (Yeast Resource Center, University of Washington, WA), and cloned into pMV262 as described (24)(25).

Isolation of CD4+ T cells.

CD4+ T cells were enriched from peripheral blood obtained from healthy donors or from commercially sourced leukapheresis donors. In both cases, PBMCs were isolated by density gradient-centrifugation method using Ficoll® Paque Plus. Total CD4+ T cells were enriched by immunomagnetic negative selection using EasySeP™ Human CD4+ T cell enrichment kit (Cat# 19052, Stem Cell Technologies). The average purity was 97-98%. CD4+ T Cells were rested overnight in RPMI1640 media (Cat# 12167Q, Lonza Bio Whittaker) supplemented with 0.1 mM non-essential amino acids (Cat#BW13-114E, Fisher Scientific), 2 mM L-glutamine ( Cat# BW17-605E, Fisher Scientific ), 1 μg/mL penicillin/streptomycin (Cat# 17-602E, Lonza), 1 mM Sodium pyruvate (Cat#BW13-115E, Fisher Scientific), 10% heat inactivated fetal bovine serum(FBS), (Cat#100-106, Gemini Bio), 4 μL/L of 2-mercaptoethanol (Cat# M3148, Millipore Sigma) and 0.2 M HEPES buffer (Cat# 17-737E, Fisher scientific) (complete media, here after referred to as M10), or in chemically pre-defined X-VIVO™15 media (with L-glutamine, gentamicin, and phenol red Cat# 04-418Q, Lonza Bioscience).

Isolation of peripheral blood monocytes.

Primary human monocytes were isolated from PBMCs by negative selection using EasySeP™ isolation kit (Cat# 19359, Stem Cell Technologies,), were rested in antibiotic free M10 for 24 h at 1x106 cell/mL before use. The average purity was 96-99%.

Activation of THP-1 cells.

THP-1 cells that had undergone less than 10 passages were stimulated with 200 ng/mL IFN-γ (Cat#570206, BioLegend) in M10 in suspension for 24 h. The average fold increase in HLA-DR expression by THP-1 cells after IFN-γ activation was five-fold as measured by flow cytometry.

Exposure of CD4+ T cells to ManLAM.

ManLAM aliquots (1 μg/μL, 40 μL) were thawed and sonicated for 25 min to emulsify the micelles. CD4+ T cells were incubated with the glycolipid at 40 μg/mL in X-VIVO™15 or M10 media for 1 h at 37°C, with rotary shaking. More than 95% of CD4+ T cells acquired ManLAM on their surface as measured by flow cytometry (supplementary Fig.S1).

Activation of CD4+ T cells.

For flow cytometric and ELISA assays, CD4+ T cells were rested in X-VIVO™15 medium at 1x106 cells/mL in culture flasks in a 37°C, 5% CO2, humidified incubator overnight. The following day CD4+ T cells were recounted, washed, and exposed to ManLAM in fresh X-VIVO™15 medium for 1 h at 37°C on a rotating shaker. Cells were then activated by plate bound anti-CD3ε (1 μg/mL) with or without soluble anti-CD28 (1 μg/mL) at 1x106 cells/mL in 24-well plates for 24 or 48 h. After stimulation, supernatants were collected for ELISA and cells stained for flow cytometric analysis of surface markers. For intracellular cytokine staining (ICS) assays, cell protein transport inhibitor Brefeldin A (Cat# 555029, BD Biosciences) was added at 1 μg/mL of media and cells were activated for 24 h prior to staining for flow cytometry.

Infection of peripheral blood monocytes with Mycobacterium bovis BCG (BCG).

Monocytes rested in antibiotic free M10 for 24 h were infected in fresh media with CFP labelled or wild type BCG that had been grown to optical density of 0.4-8 in 7H9 medium, at MOI 1:1 or 5:1 for 48 h in 24-well plates. Cultures were monitored for cell viability and changes in color of the media. Cells were washed to remove uninternalized bacteria prior to downstream assays.

Intracellular Cytokine Staining and surface marker staining for flow cytometry.

1x106 cells per condition were stained for surface markers and fixed with 1% PFA prior to acquisition. For ICS, 1x106 cells per condition were stained using the BD Cytofix/Cytoperm™ Fixation/Permeabilization kit (Cat# 554714, BD) following manufacturer’s instructions prior to 1% PFA fixation and acquisition. Cells were acquired on LSR Fortessa flow cytometer using BDFACSDiva software and data was analyzed using Flowjo software (version 10).

ELISA assays

IL-2, IFN-γ, and TNF-α ELISA were performed using ELISA kits (Cat# 88-7025-88, Cat# 88-7346-88, Cat#KHC4021, ThermoFisher Scientific) according to manufacturer’s instructions. Plates were read on a BioTek® plate reader (Highland Park, Vermont) at wavelength 450.

Analysis of LCK polarization by con-focal microscopy.

CD4+ T cells rested in M10 media were exposed to ManLAM and cultured on anti-CD3ε-coated (3 μg/mL) poly-L-lysine pretreated glass slides (Polysciences, Cat#22247) for 5 min at 37°C in 5% CO2. They were then fixed with 3% PFA, permeabilized with 1%BSA/0.1% Tx-100 for 1 min, blocked with 1%BSA for 30 min and then stained with rabbit anti-CD4 and mouse anti-LCK mAbs for 3 h at room temperature, followed by secondary goat anti-mouse IgG-AF488 and goat anti-rabbit IgG-AF594. Slides were mounted in ProLong Diamond Antifade mounting medium (Cat# P36970, Fisher Scientific) before imaging under 60x oil immersion on Hyvolution SP8 confocal microscope (Leica Microsystems). Images were analyzed and processed in Leica Application Suite X (version 3.7.4.23463) and ImageJ software.

T cell-macrophage conjugate analysis by flow cytometry.

IFN-γ activated THP-1 cells were labelled with viability compatible CMFDA dye (Cat#C7025, Thermo Scientific) at 5 μM and then loaded with Staphylococcal Enterotoxin B (SEB) (Item# BT202, Toxin Technology) at 5 μg/mL for 30 min. CD4+ T cells were labelled with 0.5 μM viability compatible Deep red dye (Cat# C34565, Thermo Scientific) and then exposed to ManLAM as described above in RPMI 1640 media. Each cell type was washed and resuspended in M10 at 50,000 cells/μL. Resuspended cells were co-cultured for 30 min at 37°C in 5% CO2 by adding 10 μL of each cell type in a 96-well U-bottom plate. Cells then were fixed in 3% PFA, 3% sucrose in 1xPBS before acquisition on an LSR Fortessa flow cytometer. At least 50,000 events were acquired per condition.

T cell-macrophage conjugate analysis by imaging flow cytometry.

CD4+ T cells were exposed to ManLAM in RPMI 1640 media as described above. IFN-γ-activated THP-1 cells were loaded with SEB at 5 μg/mL for 30 min. Each cell type was washed and resuspended at 50,000 cells/μL in RPMI 1640 supplemented with 6 mM calcium chloride (CaCl2). CD4+ T cells and THP-1 cells were then co-incubated at a ratio of 1:1 (4x106 cells in total) for 30 min at 37°C in 5% CO2 in a 96-well U-bottom plate. Cells were then fixed with 2% PFA for 20 min at 4°C. PFA was neutralized by adding 100 mM ammonium chloride (NH4Cl) for 20 min at RT. Co-cultures of CD4+ T cells and THP-1 cells were then resuspended in 200 μL staining buffer (10% FBS, 0.1% Triton X-100 in 1xPBS) for 10 min on ice. Cells were then stained for CD3, LCK and CD14 for 40 min on ice and washed twice with wash buffer (5% BSA, 1% FBS in 1xPBS) before resuspension in fixation solution. A drop of Hoechst33342 (Cat# R37605, Fisher Scientific) was added before acquisition. The cells were acquired on an Image Stream imaging flow cytometer (AmnisRImageStream, Luminex 12212 Technology Blvd, Austin TX78727), with 40x magnification at low flow rate using INSPIRE software. Brightfield channels 01 and 09 and scattering channel 06 were acquired alongside fluorescence channels. Lasers 488, 405, 658 (fluorescence), and 785 (side-scatter) were activated for acquisition. The bright field background intensities were set at 740 for each camera. Approximately 30,000 events were acquired for each sample. Data files were analyzed using IDEAS software version 6.2.187 (Amnis/EMD Millipore, 645 Elliott Ave.W. Suite 100 Seattle, WA). A conjugate was considered as an event with bright field, and Hoechst (DAPI) positive for two nuclei, and these nuclei were either CD3 or CD14 masked, with minimum aspect ratio of 0.6 for each of CD3 and CD14 masks. A valley mask applied between the two nuclei was used to define the synapse of the conjugate. Two feature derivatives were used to determine the redistribution of LCK towards the synapse; (i) percentage of total LCK (as a function of intensity) that redistributed in the valley mask, and (ii) A ratio of the brightest (maximum) pixel of LCK in the valley mask to the mean brightness of all LCK pixels in the conjugate.

Monocytes infected with CFP labelled BCG (MOI 1:1) were co-cultured with autologous CD4+ T cells in the ratio of 1:1 for 72 h in a 24-well plate. Cells were afterwards lifted off the plate using cell dissociation solution TryPLE select (Gibco, Cat#12563011) after which they were re-suspended in RPMI 1640 media supplemented with 6 mM CaCl2, with 5 μg/mL SEB. Then co-incubated for 30 min at 37°C, 5% CO2. Medium was removed and pellets incubated for more 30 min. The cells were fixed with 2% PFA at 4°C which was afterwards neutralized with 100 mM NH4Cl for 20 min at RT. Cells were then stained for CD3 and CD14 and acquired on Image Stream imaging flow cytometer and analyzed with IDEAS software as described above.

ManLAM co-localization towards the immunological synapse by confocal microscopy.

CD4+ T cells were incubated with ManLAM in RPMI 1640 media. IFN-γ activated THP-1 cells were loaded with SEB as previously described. Each cell type was resuspended at 50,000 cells/μL in RPMI 1640 media supplemented with 6 mM CaCl2. CD4+ T cells and THP-1 cells were then co-incubated at a ratio of 1:1 (4x106 cells in total) for 30 min at 37°C in 5%CO2 in a 96-well U-bottom plate. Co-cultures were then layered on poly-L-Lysine treated glass slides for 15 min at 37°C, and fixed with 3%PFA, stained with rabbit anti CD3, mouse anti CD14, and human anti ManLAM mAb followed by goat anti rabbit-AF594, goat anti mouse-AF488, and goat anti human-AF647 as secondary antibodies. Slides were read and images processed as previously described. CD4+ T cells co-cultured with primary monocytes infected with wildtype BCG (MOI 5:1) as described above were also analyzed by confocal microscopy for acquisition of ManLAM onto their cell membranes and its colocalizing towards the IS. After incubation, the cells were layered on Poly-L-Lysine treated glass slides at 37°C for 15 min. They were then stained for CD3, and ManLAM using the same primary and secondary antibodies as described previously. To determine ManLAM co-localization to the IS, in some experiments co-cultures were incubated with SEB for 1h before staining for CD3, CD86, and ManLAM. The slides were also imaged under 60x oil immersion and images processed with the same software packages as previously stated.

Statistical analysis

Prism (version 9.2.0, GraphPad, La Jolla, CA, USA) was used to analyze the data. Unless otherwise stated, one tailed paired T-test was used to analyze comparisons across experimental conditions and P values of less than 0.05 were considered significant (*p≤ 0.05, **p ≤ 0.01, ***p ≤0.001). Differences between, or ratios of paired values were considered consistent. In some experiments, Wilcoxon matched pairs signed rank test was used to compare outcomes across different donors of CD4+ T cells (*p≤ 0.05, **p ≤ 0.01, ***p ≤0.001, ****p ≤0.0001 ns = not significant).

Results

ManLAM inhibits IL-2, TNF-a and IFN-γ production by activated primary CD4+ T cells without affecting T cell inhibitory and co-stimulatory molecule expression.

We adapted a protocol used to study the effect of Mtb glycolipids on the activation of murine polyclonal CD4+ T cells to determine the extent to which ManLAM inhibits human CD4+ T cell activation (20). Resting total CD4+ T cells were purified by negative selection from PBMCs from healthy adults. Purified CD4+ T cells were then exposed to 40 μg/mL of ManLAM or medium alone for 1 h at 37°C before stimulation with plate bound anti-CD3ε and soluble anti-CD28 for 24 or 48 h for assessment of intracytoplasmic cytokine staining (ICS) in the presence of brefeldin A (1 μg/ml), and cytokine secretion by ELISA. IL-2, TNF-α and IFN-γ secretion was significantly reduced when CD4+ T cells were incubated with ManLAM prior to stimulation (Fig. 1A). These findings were confirmed and extended by flow cytometry, which revealed decreased intracellular IL-2, TNF-α, and IFN-γ expression as single cytokines (Fig.1B&C) and in terms of polyfunctionality as decreased IL-2 together with IFN-γ, or TNF-α (Fig. 1D). Anti-CD3ε without anti-CD28 served as control for suboptimal T cell activation and as comparator for the inhibitory effect of ManLAM pre-treatment on human CD4+ T cell activation. Taken together, these findings show human CD4+ T cells are susceptible to ManLAM mediated inhibition.

Fig. 1. ManLAM inhibits the activation of human CD4+ T cells.

Fig. 1

Open in a new tab

Purified human CD4+ T cells were incubated with or without ManLAM (40 μg/mL) for 1 h. CD4+ T cells were cultured in medium alone or stimulated with either plate bound anti-CD3ε alone or together with soluble anti-CD28 (both at 1μg/mL) for 24 or 48 h.

A. IL-2, TNF-α, and IFN-γ were measured in 48-h culture supernatants by ELISA. Data are the mean of two replicates for a total of three experiments from three different donors for IL-2 and TNF-α, and four experiments from four donors for IFN-γ.

B. Percentages of cytokine positive CD4+ T cells by flow cytometry after 24-h stimulation in presence of 1μg/mL of brefeldin A are shown for a representative experiment of six from six different donors.

C. Summary of percentage of cells expressing IL-2, TNF-α, and IFN-γ for six experiments from six different donors is shown.

D. Percentage of cells co-expressing IL-2 and TNF-α or IFN-γ by Boolean gating is shown for six experiments from six different donors. Data in A, C and D are represented as mean ± SEM, (*p ≤ 0.05, **p ≤ 0.01).

We next determined whether decreased cytokine production of T cells pre-treated with ManLAM was related to changes in inhibitory or co-stimulatory molecule expression. As shown in supplementary Fig. S2, ManLAM pretreatment had no effect on the expression of inhibitory receptors CTLA-4, PD-1, TIM-3 and Lag-3, or of co-stimulatory molecules CD40L and ICOS by CD4+ T cells when compared to un-treated cells. These results extend our earlier findings with antigen specific murine CD4+ T cells that exposure to ManLAM inhibits their activation as measured by reduced ability to produce cytokines without affecting T cell inhibitory and costimulatory molecule expression (17).

ManLAM downregulates the co-expression of CD25 and CD69 by CD4+ T cells, and addition of IL-2 does not reverse ManLAM mediated inhibition.

Next, we determined whether addition of exogenous IL-2 would reverse ManLAM’s inhibitory effect. Firstly, we measured the effect of ManLAM on expression of CD25 and CD69, two early T cell activation markers. CD4+ T cells were exposed to ManLAM as described above and stimulated with plate bound anti-CD3ε and soluble anti-CD28 for 24 h. ManLAM reduced co-expression of CD25 and CD69 by flow cytometry (Fig. 2A&B). On further analysis, we observed this reduction in co-expression to be driven by CD25, as there was no statistically significant difference in CD69 expression between ManLAM exposed and unexposed CD4+ T cells (Fig. 2C & supplementary Fig. S3A, B&C). By using changes in expression of CD25 and TNF-α as surrogates for ManLAM’s effect, we determined if addition of exogenous IL-2 would reverse the inhibition. CD4+ T cells were stimulated with plate bound anti-CD3ε and soluble anti-CD28 for 24 h, in the presence or absence of rIL-2 (10ng/mL). Cells were stained for CD4, CD69 and CD25, and analyzed by flow cytometry. Supernatants were collected for TNF-α ELISA. IL-2 did not reverse the effects of ManLAM on CD25 and TNF-α expression (Fig.2D&E). Addition of rIL-2 to T cells unexposed to ManLAM significantly increased expression of TNF-α (Fig.2E). Decreased expression of CD25 by ManLAM, with no effect on CD69, and failure of IL-2 to reverse this inhibition suggests disruption of the TCR/IL-2R signaling axis leading to sub-optimal activation of the cells.

Fig. 2. ManLAM downregulates CD25 and CD69 co-expression by human CD4+ T cells, and addition of recombinant human IL-2 (rIL-2) does not reverse their ManLAM mediated inhibition.

Fig. 2

Open in a new tab

Purified human CD4+ T cells were incubated with or without ManLAM (40 μg/mL) for 1 h. CD4+ T cells were cultured in medium alone or stimulated with either plate bound anti-CD3ε alone or together with soluble anti-CD28 (both at 1μg/mL) for 24 h. Cells were then stained for CD4, CD69, and CD25, and analyzed by flow cytometry.

A. Flow cytometric graphs of CD25 and CD69 co-expression across four experimental conditions from a representative experiment of four from three donors.

B. Summary of CD25 and CD69 co-expression by CD4+ T cells for four experiments from three donors.

C. Summary of CD25 MFI for four experiments from three donors. Data in B&C are represented as mean ± SEM, (**p ≤ 0.01, ***p ≤0.001).

(D&E) Purified human CD4+ T cells were incubated with or without ManLAM (40 μg/mL) for 1 h. CD4+ T cells then were stimulated with plate bound anti-CD3ε and soluble anti-CD28 for 24 h, in presence or absence of rIL-2 (10ng/mL). Cells were then stained for CD4, CD69, and CD25, and analyzed by flow cytometry. Supernatants were collected for TNF-α by ELISA.

D. Summary data of impact of rIL-2 on CD25 and CD69 co-expression by CD4+ T cells of four experiments from three donors.

E. Summary data of impact of rIL-2 on TNF-α secretion measured by ELISA from four experiments from three donors. Data in D&E are represented as mean ± SEM, (*p≤ 0.05, **p ≤ 0.01).

ManLAM inhibits conjugate formation between CD4+ T cells and THP-1 macrophages and reduces translocation of LCK towards the activation interface of CD4+ T cells.

Having determined that ManLAM inhibits T cell activation and cytokine production without inducing inhibitory receptor expression, we next focused on the impact of Mtb glycolipids on the interaction between CD4+ T cells and macrophages, i.e., the immunological synapse (IS). An artificial activation platform (pseudo-APC) was created by coating glass slides with anti-CD3ε and adding ManLAM-exposed or unexposed CD4+ T cells for 5 min. Cells on slides were then fixed and stained for LCK and CD4, followed by confocal microscopy. Pre-incubation of CD4+ T cells with ManLAM reduced polarization of LCK towards the artificial activation interface compared to ManLAM unexposed T cells (Fig. 3A&B).

Fig. 3. ManLAM blocks the mobilization of LCK towards the activation interface and inhibits the formation of conjugates between CD4+ T cells and THP-1 cells.

Fig. 3

Open in a new tab

(A&B) Purified human CD4+ T cells were incubated with or without ManLAM (40 μg/mL) for 1 h. T cells then were cultured on anti-CD3ε (3 μg/mL) coated slides for 5 min, fixed, permeabilized, and stained with primary mouse anti-LCK and rabbit anti-CD4. This was followed with secondary AF488-conjugated goat anti-Mouse IgG and AF594-conjugated goat anti-Rabbit IgG. Fixed Cells were imaged under 60x oil immersion by confocal microscopy.

A. Representative images for one of two experiments from two donors of CD4+ T cells are shown.

B. Enlarged images of two CD4+ T cells, one exposed and another unexposed to ManLAM prior to incubation on anti-CD3ε coated slides. Images are representative of one of two experiments from two donors.

(C, D&E) THP-1 macrophages were stimulated with IFN-γ (200 ng/mL) for 24 h. Macrophages were labelled with viability compatible CMFDA dye and loaded with 5 μg/mL SEB for 30 min. Cells were washed and co-cultured with human CD4+ T cells that had been labelled with viability compatible Deep red dye, and incubated with or without ManLAM ( 40 μg/mL) for 1 h. CD4+ T cells and THP-1 cells were co-cultured at a ratio of 1:1 for 30 min at 37°C in 5% CO2 before analysis by flow cytometry.

C. The gating strategy used to evaluate CD4+ T cell-THP-1 conjugates by flow cytometry is representative of four experiments from four donors.

D. Flow cytometry graphs from a single representative experiment of four from four donors demonstrating the detection of conjugates across four experimental conditions.

E. Summary results for four experiments from four donors showing percentage of conjugates formed across the experimental conditions (mean ± SEM, paired t test *p≤ 0.05).

To determine the effect of ManLAM on the formation of conjugates between CD4+ T cells and THP-1 macrophages, THP-1 cells were stimulated for 24 h with IFN-γ before labelling with cell tracking CMFDA dye. The labelled THP-1 cells were then treated with staphylococcal enterotoxin B (SEB) to bind to MHC-II, allowing them to engage with Vβ chain expressing T cells. SEB-treated THP-1 cells were then co-cultured for 30 min with ManLAM exposed and unexposed Deep red dye-labelled CD4+ T cells to allow for TCR-MHC-II crosslinking. Co-cultured cells were analyzed by flow cytometry to determine CMFDA-Deep red dye (double positive) events, i.e., CD4+ T cell–THP-1 conjugates. As shown in Fig. 3C, D&E, ManLAM exposed CD4+ T cells formed fewer conjugates compared to non-exposed ones. These data suggest IS disruption as a contributing factor to ManLAM mediated T cell inhibition.

To more definitively evaluate conjugate formation and the nature of the IS between CD4+ T cells and SEB-loaded THP-1 cells, we used imaging flow cytometry (IFC). IFC integrates quantitative image acquisition and analysis, and thus the ability to interrogate morphological changes and quantitative translocation of proteins within cellular regions at individual cell and population level (26) (27) (28). IFC was used not only to detect true CD4+ T cell-THP-1 conjugates but also to measure differences in LCK localization to the IS in CD4+ T cells exposed or unexposed to ManLAM. For these experiments we used the same experimental design as used for experiments described in Fig. 3C-E, i.e., co-culture of SEB-loaded THP-1 and CD4+ T cells. Supplementary Fig. S4B shows the IFC gating strategy. CD14 and DAPI (Hoechst) were used to identify THP-1 cells, and CD3 and DAPI to identify CD4+ T cells. Initial gating selected CD14 and CD3 double positive events. To exclude double positive events with more than one THP-1 or more than one CD4+ T cell, we gated on events with aspect ratios > 0.6 for either CD3 or CD14 masks. This allowed focusing on double positive events of single CD3+ and CD14+ cells. Using this approach, we first compared the rates of conjugate formation between ManLAM pre-treated and non-treated CD4+ T cells co-cultured with SEB-loaded THP-1 cells. We found decreased numbers of CD3+ CD14+ dual-positive conjugate events when CD4+ T cells were pretreated with ManLAM (Fig.4A). Fig. 4B shows representative images demonstrating that true CD4+ T cell-THP-1 conjugates were detected by IFC. Fig. 4C summarizes the results of four experiments showing a 23% reduction in CD4+ T cell-THP-1 conjugate formation when T cells were pretreated with ManLAM. These IFC experiments confirm our conventional flow cytometry and confocal microscopy findings that CD4+ T cells treated with ManLAM form fewer conjugates compared to ManLAM non-treated T cells.

Fig. 4. By imaging flow cytometry (IFC), ManLAM reduces the number of conjugates formed between CD4+ T cells and THP-1 cells.

Fig. 4

Open in a new tab

Purified human CD4+ T cells were incubated with or without ManLAM (40 μg/mL) for 1 h. THP-1 cells were loaded with SEB (5 μg/mL) for 30 min. Cells were washed and resuspended at 50,000 cells/μl in RPMI 1640 supplemented with 6 mM calcium chloride. CD4+ T cells and THP-1 cells were co-cultured at 1:1 ratio for 30 min at 37°C in 5% CO2. Co-cultured cells were fixed and stained for CD3, and CD14 for 40 min on ice. A drop of Hoechst (DAPI) dye was added to each sample before acquisition. Samples were acquired on Amnis Image Stream imaging flow cytometer at 40x magnification at low flow rate using INSPIRE software and analyzed using IDEAS software. Approximately 30,000 events were acquired and analyzed per sample. A conjugate was defined as an event imaged by bright field that was also positive for Hoechst dye, CD3 and CD14 with an aspect ratio ≥ 0.6 for both CD3 and CD14 masks, i.e., only conjugates of single CD4+ T cells and THP-1 cells were included in analysis.

A. Representative dot plots of conjugates as a percentage of total gated CD3+ events from one of four experiments from two donors.

B. Representative IFC images showing conjugates from one of four experiments from two donors.

C. Summary results for four experiments from two donors presented as percentage of conjugates formed across the different experimental conditions (mean ± SEM, paired t test *p≤ 0.05).

ManLAM reduces the localization of LCK towards the CD4+ T cell-macrophage synapse as measured by IFC.

In addition to counting true conjugates, IFC allows assessment of the quality of the activation interface between SEB-loaded APC and CD4+ T cells, allowing us to use LCK localization to the IS as measure of CD4+ T cell activation. As shown in Fig. 5A, we measured LCK localization to the IS using a valley mask between the two nuclei of CD4+ T cell and THP-1 cell that were forming a conjugate. The localization of LCK to IS can be measured by both LCK redistribution i.e., (% of LCK in valley mask compared to total cellular LCK) and the brightness of LCK (maximum pixel) in the valley mask compared to the mean brightness (mean pixel) of LCK over the entire conjugate (Fig. 5B). With ManLAM treated CD4+ T cells, we find that there is approximately a 24% reduction in CD4+ T cells that form conjugates with at least 20% of LCK within the IS compared to ManLAM untreated T cells (Fig. 5C,D&E). Overall, these experiments demonstrate that ManLAM pretreatment not only reduced conjugate formation but also impacted the activation and LCK translocation in CD4+ T cells that were able to form conjugates.

Fig. 5. Exposure to ManLAM reduces the percentage of conjugates with at least 20% of total LCK in the IS of CD4+ T cells and THP-1 cells.

Fig. 5

Open in a new tab

Human CD4+ T cells were incubated with or without ManLAM (40 μg/mL) for 1 h, and THP-1 cells were treated with SEB (5 μg/mL), then co-cultured, stained for CD3, CD14, and LCK and acquired as described in Fig. 4.

A. An immunological synapse (IS) was defined by applying the valley mask feature of IDEAS software to the interface of the Hoechst dye-stained nuclei of CD3+ and CD14+ cells as shown in representative image from one of four experiments from two donors.

B. Two parameters were used to measure LCK translocation to the IS: (i) redistribution of LCK (as % of total cellular LCK) to the IS in the valley mask, and (ii) the ratio of maximum brightness (maximum pixel) of LCK in the IS to the mean brightness (mean pixel) of LCK over the entire cell.

C. IFC dot plots for conjugates with at least 20% of LCK in the IS as a percentage of total CD3+ events gated when the parameters described in Fig. 5B were applied. Representative dot plots of one experiment of four from two donors are shown.

D.IFC images showing translocation of LCK to the IS. Representative images of one experiment of four from two donors are shown.

E. Summary data from four experiments from two independent donors of CD4+ T cells (mean ± SEM, paired t test *p≤ 0.05).

ManLAM colocalizes with CD4+ T cells co-cultured with BCG- infected monocytes, and CD4+ T cells form fewer conjugates with infected vs non-infected monocytes.

Our previous studies demonstrated that ManLAM and other glycolipids can be released in the form of bacterial microvesicles by macrophages infected with mycobacteria (16)(19). Thus, we sought to determine the extent to which ManLAM from human monocytes infected with Mycobacterium bovis-BCG (BCG) colocalizes with human CD4+ T cells, and the impact of BCG infection on the IS. Primary human CD4+ T cells were co-cultured with autologous mononuclear phagocytes. We also took advantage of recently developed high affinity human anti-ManLAM mAb L1AM04 to detect ManLAM in CD4+ T cells (21). Using mAb L1AM04, we directly identified ManLAM in the membrane of ManLAM pretreated CD4+ T cells (supplementary Fig. S1). In some CD4+ T cells we identified increased amounts of ManLAM directly in the IS with SEB-pretreated macrophages (Fig. 6A).

Fig. 6. ManLAM is transferred from BCG-infected monocytes to CD4+ T cells, localizes to the IS and reduces conjugate formation of CD4+ T cells with infected monocytes.

Fig. 6

Open in a new tab

A. ManLAM localizes to the IS as determined by confocal microscopy. Purified human CD4+ T cells were incubated with ManLAM (40 μg/mL) for 1 h, and co-cultured at 1:1 with THP-1 cells loaded with SEB (5 μg/mL) for 30 min. Co-cultured cells were layered on glass slides and incubated for 15 min and then stained for CD3, CD14, and ManLAM for 3 h followed by respective secondary Abs for 1 h. Slides were imaged under 60x oil immersion. Representative confocal microscopy images from one of two experiments from two donors are shown with ManLAM localizing to the synapse (white arrow).

B. ManLAM is transferred to CD4+ T cells by BCG infected monocytes. Primary monocytes were infected with BCG for 48 h at MOI 5:1 before addition of autologous CD4+ T cells. CD4+ T cells and BCG-infected monocytes were co-cultured for 72 h. Co-cultures were then layered on glass slides and incubated for 15 min and then stained with rabbit anti-CD3, and human anti-LAM (L1AM04) for 3 h followed by followed by the respective secondary Abs for 1h. Slides were imaged under 60x oil immersion. Representative confocal microscopy images from one of three experiments from three donors showing ManLAM staining of CD4+ T cells (white arrow) are shown.

C. ManLAM localizes to the IS when CD4+ T cells are co-cultured with BCG infected monocytes. Primary monocytes were infected with BCG at MOI 5:1 for 48 h, co-cultured with autologous CD4+ T cells as in B above. Afterwards SEB was added for 1 h. Co-cultures were layered on glass slides and incubated for 15 min and then stained with Rabbit anti-CD3, mouse anti-CD86, and human anti-LAM (L1AM04) for 3 h followed by the respective secondary Abs for 1 h. Slides were imaged under 60x oil immersion. Representative confocal microscopy images from one of three experiments from three donors showing ManLAM localizing to the IS of CD4+ T cells co-cultured with BCG infected monocytes (white arrow) are shown.

(D, E&F) BCG infection reduces CD4+ T cell-monocyte conjugate formation. Primary monocytes were infected with CFP-BCG for 48 h at MOI 1:1 before addition of autologous CD4+ T cells. CD4+ T cells and BCG-infected monocytes were co-cultured for 72 h. Then SEB was added for 1 h. Co-cultured cells were stained with AF488 conjugated anti-CD3, and PE conjugated anti-CD14 mAbs and acquired for IFC on Image Stream imaging flow cytometer.

D. IFC gating strategy in which two populations of CD14+ events were defined: CD14+ BCG/CFP+ (infected) and CD14+ BCG/CFP− (non-infected). Representative IFC dot plots from one experiment of three from three donors are shown.

E. Images of CD4+ T cell-monocyte conjugates with infected monocytes (CD3+CD14+ BCG/CFP+). Representative images from one experiment of three from three donors are shown.

F. Summary percentages of three experiments from three donors showing BCG infected vs BCG uninfected monocytes that form conjugates with CD4+ T cells (***p ≤0.001).

We next determined if ManLAM can be acquired by CD4+ T cells co-cultured with BCG infected monocytes, and the ability of infected monocytes to form conjugates. Primary monocytes were infected with wild type BCG and co-cultured with autologous CD4+ T cells for 72 h before adding SEB for 1 h and processing cells for confocal imaging. Confocal images of CD4+ T cells co-cultured with monocytes infected with wild type BCG at MOI 5:1 demonstrate the transfer of ManLAM from infected monocytes to CD4+ T cells (Fig. 6B) with a suggestion in some images of increased ManLAM in the IS with monocytes (Fig. 6C). IFC was used to quantify the ability of BCG-infected monocytes to form conjugates with CD4+ T cells. At MOI 1:1, BCG infected monocytes formed 50% fewer conjugates with CD4+ T cells than uninfected monocytes (Fig. 6D, E&F). Thus, BCG-infected monocytes can transfer ManLAM to CD4+ T cells resulting in less efficient conjugate formation.

Discussion.

Our results demonstrate the ability of Mtb’s major cell wall glycolipid, ManLAM, to inhibit human CD4+ T cell activation in three areas. First, we extended our functional observations from murine studies to primary human CD4+ T cells. Second, we explored the impact of ManLAM on the formation of the IS between human CD4+ T cells and macrophages, and LCK migration towards the IS. Third, we determined ManLAM’s transfer from BCG-infected human macrophages to CD4+ T cells and the impact of BCG infection on the IS.

ManLAM inhibited the production of IL-2, TNF-α and IFN-γ, and expression of CD25 without significantly changing the expression of CD69. Expression of inhibitory receptors CTLA-4, PD-1, TIM-3 and Lag-3, or co-stimulatory molecules CD40L and ICOS was not affected by ManLAM. These findings extended earlier findings with murine to human CD4+ T cells that the mechanism of ManLAM induced T cell hypo-responsiveness is distinct from disturbing the balance of costimulatory and inhibitory receptor signaling (17). The absence of inhibitory molecule upregulation or downregulation of CD69 argues against induction of CD4+ T cell exhaustion (29). Suppression of CD25 expression supports disruption of the TCR/IL-2R signaling axis due to ManLAM’s capacity to inhibit TCR signaling by insertion in CD3/TCR containing lipid rafts which in turn impacts IS formation (17).

Since professional APCs are important for CD4+ T cell responses to Mtb bacilli and their antigens, and mononuclear phagocytes are a niche for Mtb growth, we focused on the T cell- macrophage IS. We first evaluated conjugate formation between primary CD4+ T cells and THP-1 macrophages using conventional flow cytometry. ManLAM exposed CD4+ T cells formed fewer conjugates with THP-1 macrophages when SEB was used to cross-link TCR with MHC-II on macrophages. IFC provided higher analytical stringency for conjugate enumeration by focusing on individual CD4+ T cell-macrophage conjugates, in addition to allowing analysis of larger numbers of individual events (26)(28)(27). IFC confirmed that ManLAM exposure reduced macrophage-T cell conjugates but less significantly: 40% by conventional flow cytometry vs 20% reduction by IFC).

IFC, aside from detecting conjugates, also allowed measurement of LCK localization to the T-cell-macrophage interface of successful conjugates. LCK, a Src kinase, is mobilized to the IS by CD4 (and CD8) co-receptors upon T cell-APC engagement (30)(31)(32). LCK phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on CD3ε (33)(34). ZAP70 kinase docks to phosphorylated CD3ε ITAMs and is then phosphorylated by LCK (33) (34). Thus, mobilization of LCK towards the IS is essential for T cell activation through the TCR-CD3 complex. Our previous studies showed that Mtb derived glycolipids including ManLAM block phosphorylation of ZAP70 and adaptor protein LAT (20)(35). IFC showed that ManLAM-exposed CD4+ T cells that did form conjugates had reduced localization of LCK to the IS, measured both by the % of total LCK found in the IS and the brightness of LCK signal in the IS. Thus, IFC determined that ManLAM exposure not only subtly reduced the number of CD4+ T cell-macrophage conjugates but that when conjugates were formed there was a reduction in LCK localization to the IS. Confocal microscopy of anti-CD3 coated slides as pseudo-APC confirmed that ManLAM reduced LCK mobilization towards the activation interface. Thus, complementary experimental approaches demonstrate the impact of ManLAM exposure on IS formation between monocytes and primary human CD4+ T cells. Combining modestly reduced conjugate formation with modestly reduced suboptimal LCK localization are likely additive and together provide a mechanism for substantial ManLAM-mediated inhibition of CD4+ T cell activation.

ManLAM can be readily detected in Mtb infected tissues in animal models, clinically ManLAM is found in the urine, sputum, and serum of persons with advanced TB, and remains a target for new TB diagnostics in pediatric and HIV-TB (22) (21)(36) (37). Recent studies show that Mtb and other mycobacteria produce bacterial microvesicles that can be released directly, or their molecules incorporated into exosomes by infected macrophages (16)(19). Thus, ManLAM and other glycolipids are readily found in the micro-environment of Mtb infected cells and tissues (19). It should be noted that while this study focuses on ManLAM, the major glycolipid, it’s precursors PIM and LM also have T cell inhibitory activity (19). The availability of newer and more sensitive mAbs for ManLAM and its components, allowed us to extend our studies to the direct transfer of ManLAM from infected macrophages to CD4+ T cells (21)(22). Confocal microscopy showed ManLAM transfer from BCG infected macrophages to CD4+ T cells and colocalization to the IS. Interestingly, both conjoined and non-conjoined CD4+ T cells stained positive for ManLAM when cultured with BCG infected macrophages, indicating that direct contact isn’t required for ManLAM to reach T cells. However, when CD4+ T cells were co-cultured with a mixture of BCG infected and uninfected macrophages, that proximity to the source of ManLAM mattered.

Our studies have some limitations. First, M. bovis BCG is not identical to Mtb, although they share the same ManLAM precursors and ManLAM. All ManLAM experiments were with ManLAM purified from Mtb. Second, it is possible that naïve and memory CD4+ T cells differ in sensitivity to the inhibitory activity of ManLAM. We used purified total CD4+ T cells, which contain cells of both phenotypes. The focus of our studies was on the interaction of CD4+ T cells with macrophages, which in the context of Mtb infection is primarily mediated by memory/effector T cells. Third, the reduction in productive IS formation with CD4+ T cells by BCG-infected macrophages may involve mechanisms in addition to ManLAM transfer. BCG infection might affect the overall efficiency of macrophages to serve as APC and form productive IS, in addition to ManLAM’s effect. Four, IFC experiments required large numbers of CD4+ T cells and monocytes for which we used leukapheresis products which limited the number of donors we could use. This may reduce the generalizability of the results. The IFC experiments were critical for extending and gaining insight into how ManLAM interfered with IS integrity and inhibited CD4+ T cell activation. Figure legends for all data shown explicitly state how many experiments were performed and the number of donors used.

Overall, our findings demonstrate ManLAM to likely inhibit activation of T cells by disrupting productive engagement of TCR with cognate MHC-peptide complex even when presented by a competent APC. Suboptimal activation may render CD4+ T cells anergic and/or hypofunctional. In earlier studies, ManLAM exposed murine CD4+ T cells were found to become anergic and expressed increased GRAIL. This hypofunctional state persisted even when the glycolipid was cleared from the T cell plasma membrane (17). Anergy is associated with upregulation of other E3 ligases such as Cbl-b and Itch that target proximal TCR signaling molecules (e.g., LCK, ZAP70 and LAT) for proteasomal degradation (38)(39)(40)(41)(42). Anergy can result from poor T cell-APC engagement such as suboptimal IS formation.

Secretion of mycobacterial glycolipids such as ManLAM by Mtb infected macrophages may result in poor engagement of CD4+ T cells and possibly anergy due to suboptimal IS formation and CD3/TCR signaling. This provides Mtb a mechanism for evasion of T cell recognition and enhances its survival in its infectious niche: the macrophage.

Supplementary Material

1

Key Points.

ManLAM suppresses productive activation of human CD4+ T cells.

ManLAM can be acquired by CD4+ T cells from BCG-infected monocytes in co-cultures.

ManLAM disrupts the integrity of the CD4+ T cell- macrophage immunological synapse.

Acknowledgments

We thank Scott Reba for technical assistance. We are grateful to Case Western Reserve University Light Microscopy Imaging Core facility, and the Cytometry & Imaging Microscopy of Shared Resource of the Case Comprehensive Cancer Center. We extend our appreciation to Richard DeMarco, the Instrument Field Applications Scientist at Luminex Corporation for his help concerning Imaging flow cytometry data analysis.

This work was supported by the National Institutes of Health Grants D43TW010319 (IM, WHB), AI034343 (CVH), AI146329 (JMA), AI027243 (WHB) and Contract No. 75N93019C00071 (WHB) and the Cytometry & Imaging Microscopy of Shared Resource of the Case Comprehensive Center (P30CA043703).

Abbreviation:

APC

Antigen presenting cell

BCG

Mycobacterium bovis BCG

ICS

Intracellular cytokine staining

IFC

Imaging flow cytometry

IL-2R

IL-2 receptor

IS

Immunological synapse

LTBI

Latent Mycobacterium tuberculosis infection

ManLAM

Mannosylated lipoarabinomannan

MFI

Median fluorescence intensity

MOI

Multiplicity of infection

Mtb

Mycobacterium tuberculosis

PFA

Paraformaldehyde

RT

Room temperature

TCR

T cell receptor

References

  • 1.Sia JK, and Rengarajan J. 2019. Immunology of Mycobacterium tuberculosis Infections . Microbiol Spectr 7: 1–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Srivastava S, Ernst JD, and Desvignes L. 2014. Beyond macrophages: The diversity of mononuclear cells in tuberculosis. Immunol Rev 262: 179–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kozakiewicz L, Phuah J, Flynn J, and Chan J. 2013. The role of B cells and humoral immunity in mycobacterium Tuberculosis infection. Adv Exp Med Biol 783: 225–250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Porcelli SA, and Jacobs WR. 2019. Exacting Edward Jenner’s revenge: The quest for a new tuberculosis vaccine. Sci Transl Med 11: 1–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Harding CV, and Boom WH. 2010. Regulation of antigen presentation by Mycobacterium tuberculosis: A role for Toll-like receptors. Nat Rev Microbiol 8: 296–307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Prezzemolo T, Guggino G, La Manna MP, Liberto D. Di Di, Dieli F, and Caccamo N. 2014. Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Front Immunol 5: 1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.World Health Organization. Global tuberculosis report 2018,.
  • 8.Henry Boom W, Schaible UE, and Achkar JM. 2021. The knowns and unknowns of latent Mycobacterium tuberculosis infection. Journal of Clinical Investigation 131: 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Jasenosky LD, Scriba TJ, Hanekom WA, and Goldfeld AE. 2015. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev 264: 74–87. [DOI] [PubMed] [Google Scholar]
  • 10.Barber-Mayer KD, and Barber DL. 2015. Innate and adaptive cellular immune responses to Mycobacterium tuberculosis infection. Cold Spring Harb Perspect Med 5: 1–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA, and Pantaleo G. 2011. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 17: 372–377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lindestam Arlehamn CS, Gerasimova A, Mele F, Henderson R, Swann J, Greenbaum JA, Kim Y, Sidney J, James EA, Taplitz R, McKinney DM, Kwok WW, Grey H, Sallusto F, Peters B, and Sette A. 2013. Memory T Cells in Latent Mycobacterium tuberculosis Infection Are Directed against Three Antigenic Islands and Largely Contained in a CXCR3+CCR6+ Th1 Subset. PLoS Pathog 9: 1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Schaible UE, Weiss unter, and Weiss G. 2015. G€ unter Weiss Macrophage defense mechanisms against intracellular bacteria. Immunol Rev 264: 182–203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Portal-Celhay C, Tufariello JM, Srivastava S, Zahra A, Klevorn T, Grace PS, Mehra A, Park HS, Ernst JD, Jacobs WR, and Philips JA. 2016. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4+ T-cell activation. Nat Microbiol 2: 1–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Srivastava S, Grace PS, and Ernst JD. 2016. Antigen Export Reduces Antigen Presentation and Limits T Cell Control of M. tuberculosis. Cell Host Microbe 19: 44–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Athman JJ, Wang Y, McDonald DJ, Boom WH, Harding CV, and Wearsch PA. 2015. Bacterial Membrane Vesicles Mediate the Release of Mycobacterium tuberculosis Lipoglycans and Lipoproteins from Infected Macrophages . The Journal of Immunology 195: 1044–1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sande OJ, Karim AF, Li Q, Ding X, Harding CV, Rojas RE, and Boom WH. 2016. Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis Induces CD4 + T Cell Anergy via GRAIL . The Journal of Immunology 196: 691–702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Prados-Rosales R, Baena A, Martinez LR, Luque-Garcia J, Kalscheuer R, Veeraraghavan U, Camara C, Nosanchuk JD, Besra GS, Chen B, Jimenez J, Glatman-Freedman A, Jacobs WR, Porcelli SA, and Casadevall A. 2011. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. Journal of Clinical Investigation 121: 1471–1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Athman JJ, Sande OJ, Groft SG, Reba SM, Nagy N, Wearsch PA, Richardson ET, Rojas R, Boom WH, Shukla S, and Harding CV. 2017. Mycobacterium tuberculosis Membrane Vesicles Inhibit T Cell Activation . The Journal of Immunology 198: 2028–2037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mahon RN, Rojas RE, Fulton SA, Franko JL, Harding CV, and Boom WH. 2009. Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4 + T-cell activation by interfering with proximal T-cell-receptor signaling. Infect Immun 77: 4574–4583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ishida E, Corrigan DT, Malonis RJ, Hofmann D, Chen T, Amin AG, Chatterjee D, Joe M, Lowary TL, Lai JR, and Achkar JM. 2021. Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes. Commun Biol 4: 1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Corrigan DT, Ishida E, Chatterjee D, Lowary TL, and Achkar JM. 2022. Monoclonal antibodies to lipoarabinomannan/arabinomannan – characteristics and implications for tuberculosis research and diagnostics. Trends Microbiol 31: 22–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Li Q, Karim AF, Ding X, Das B, Dobrowolski C, Gibson RM, Quiñones-Mateu ME, Karn J, and Rojas RE. 2016. Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis. Sci Rep 6: 1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Valdivia RH, Hromockyj AE, Monack D, Ramakrishnan L, and Falkow S. 1996. Applications for green fluorescent protein (GFP) in the study of host-pathogen interactions *. Gene 173: 47–52. [DOI] [PubMed] [Google Scholar]
  • 25.Pecora ND, Fulton SA, Reba SM, Drage MG, Simmons DP, Urankar-Nagy NJ, Boom WH, and Harding C. v.. 2009. Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cell Immunol 254: 94–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Barteneva NS, Fasler-Kan E, and Vorobjev IA. 2012. Imaging Flow Cytometry: Coping with Heterogeneity in Biological Systems. Journal of Histochemistry and Cytochemistry 60: 723–733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Payes C, Friend JA,S, and Helguer G. 2012. Cell Interaction Analysis by Imaging Flow Cytometry. In Cell Interaction InTech. [Google Scholar]
  • 28.Ahmed F, Friend S, George TC, Barteneva N, and Lieberman J. 2009. Numbers matter: Quantitative and dynamic analysis of the formation of an immunological synapse using imaging flow cytometry. J Immunol Methods 347: 79–86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Crespo J, Sun H, Welling TH, Tian Z, and Zou W. 2013. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25: 214–221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Barber EK, DEV DASGUPTAt J, Schlossman SF, Trevillyan JM, and Rudd CE. 1989. The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p561ck) that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci. USA 86: 3277–3281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Rudd CE, Trevillyan JM, DEV DASGUPrAt J, Wong LL, and Schlossman SF. 1988. The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc. Nati. Acad. Sci. USA 85: 5190–5194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Filipp D, Zhang J, Leung BL, Shaw A, Levin SD, Veillette A, and Julius M. 2003. Regulation of Fyn through translocation of activated Lck into lipid rafts. Journal of Experimental Medicine 197: 1221–1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Huse M. 2009. The T-cell-receptor signalling network. J Cell Sci 122: 1269–1273. [DOI] [PubMed] [Google Scholar]
  • 34.Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, and Weiss A. 2009. The structure, regulation, and function of ZAP-70. Immunol Rev 228: 41–57. [DOI] [PubMed] [Google Scholar]
  • 35.Mahon RN, Sande OJ, Rojas RE, Levine AD, Harding CV, and Henry Boom W. 2012. Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cell Immunol 275: 98–105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Conesa-Botella A, Massinga Loembé M, Manabe YC, Worodria W, Mazakpwe D, Luzinda K, Mayanja-Kizza H, Miri M, Mbabazi O, Koole O, Kestens L, and Colebunders R. 2011. Urinary Lipoarabinomannan as Predictor for the Tuberculosis Immune Reconstitution Inflammatory Syndrome. Clin Sci 58: 463–468. [DOI] [PubMed] [Google Scholar]
  • 37.Choudhary A, Patel D, Honnen W, Lai Z, Prattipati RS, Zheng RB, Hsueh Y-C, Gennaro ML, Lardizabal A, Restrepo BI, Garcia-Viveros M, Joe M, Bai Y, Shen K, Sahloul K, Spencer JS, Chatterjee D, Broger T, Lowary TL, and Pinter A. 2018. Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of Mycobacterium tuberculosis , and Complexity of Antibody Specificities toward This Antigen . The Journal of Immunology 200: 3053–3066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Tang R, Langdon WY, and Zhang J. 2019. Regulation of immune responses by E3 ubiquitin ligase Cbl-b. Cell Immunol 340: 1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Schmidt MHH, and Dikic I. 2005. The Cbl interactome and its functions. Nat Rev Mol Cell Biol 6: 907–918. [DOI] [PubMed] [Google Scholar]
  • 40.Doherty M, Osborne DG, Browning DL, Parker DC, and Wetzel SA. 2010. Anergic CD4 + T Cells Form Mature Immunological Synapses with Enhanced Accumulation of c-Cbl and Cbl-b . The Journal of Immunology 184: 3598–3608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mueller DL 2004. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5: 883–890. [DOI] [PubMed] [Google Scholar]
  • 42.Park Y, seung Jin H, Aki D, Lee J, and Liu YC. 2014. The ubiquitin system in immune regulation. In Advances in Immunology vol. 124. Academic Press Inc. 17–66. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
NIHMS1927963-supplement-1.pdf (6.7MB, pdf)

RESOURCES